Compare COGT & KMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | KMX |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.0B |
| IPO Year | 2018 | 2002 |
| Metric | COGT | KMX |
|---|---|---|
| Price | $38.44 | $41.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 17 |
| Target Price | $36.21 | ★ $40.08 |
| AVG Volume (30 Days) | 1.7M | ★ 2.6M |
| Earning Date | 05-05-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.29 |
| EPS | N/A | ★ 2.46 |
| Revenue | $7,871,000.00 | ★ $26,353,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,581.80 | $0.89 |
| P/E Ratio | ★ N/A | $16.25 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.72 | $30.40 |
| 52 Week High | $43.73 | $82.79 |
| Indicator | COGT | KMX |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 48.57 |
| Support Level | $36.52 | $39.57 |
| Resistance Level | $41.02 | $43.10 |
| Average True Range (ATR) | 1.82 | 1.63 |
| MACD | 0.31 | -0.02 |
| Stochastic Oscillator | 88.75 | 51.04 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
CarMax sells, finances, and services used and new cars through a chain of over 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 83% of fiscal 2025 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2025, the company retailed and wholesaled 789,050 and 544,312 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in calendar 2024. It seeks over 5% share. CarMax is based in Richmond, Virginia.